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ABSTRACT
We describe the synthesis and characterization of a
5’ conjugate between a 2’-O-Me phosphorothioate
antisense oligonucleotide and a bivalent RGD
(arginine–glycine–aspartic acid) peptide that is a
high-affinity ligand for the avb3 integrin. We used
avb3-positive melanoma cells transfected with a
reporter comprised of the firefly luciferase gene
interrupted by an abnormally spliced intron. Intra-
nuclear delivery of a specific antisense oligonucleo-
tide (termed 623) corrects splicing and allows
luciferase expression in these cells. The RGD–623
conjugate or a cationic lipid-623 complex produced
significant increases in luciferase expression, while
‘free’ 623 did not. However, the kinetics of luciferase
expression was distinct; the RGD–623 conjugate
produced a gradual increase followed by a gradual
decline, while the cationic lipid-623 complex caused
a rapid increase followed by a monotonic decline.
The subcellular distribution of the oligonucleotide
delivered using cationic lipids included both cyto-
plasmic vesicles and the nucleus, while the RGD–623
conjugate was primarily found in cytoplasmic vesi-
cles that partially co-localized with a marker for
caveolae. Both the cellular uptake and the biological
effect of the RGD–623 conjugate were blocked by
excess RGD peptide. These observations suggest
that the bivalent RGD peptide–oligonucleotide con-
jugate enters cells via a process of receptor-
mediated endocytosis mediated by the avb3 integrin.
INTRODUCTION
Antisense oligonucleotides, small interfering RNAs
(siRNA) and micro RNAs (miRNA) have elicited great
interest both as laboratory reagents and as possible
therapeutic entities. A number of issues associated with
use of oligonucleotides, including potency and stability in
the biological milieu, have been addressed through a
variety of chemical modiﬁcations (1–3). However, in terms
of therapeutic use of antisense, siRNA or miRNA
oligonucleotides, a key remaining issue is that of eﬀective
delivery (4,5). There is abundant evidence that both
antisense and siRNA oligonucleotides can exert therapeu-
tic eﬀects in animal models when administered as ‘free’
compounds, that is, in the absence of any delivery agent
(6–8). Moreover, a number of clinical trials of both
antisense and siRNA agents as free compounds are
underway (9). Nonetheless, many investigators believe
that the therapeutic potential of oligonucleotides could be
improved by use of appropriate delivery systems.
A variety of approaches have been used to enhance
delivery of siRNA and antisense oligonucleotides. In the
case of siRNA, viral vector systems are an obvious
important possibility (10–12). Various synthetic nanocar-
riers including liposomes, polymeric nanoparticles and
dendrimers have also been extensively studied as oligonu-
cleotide delivery agents (13–17). However, the particulate
nature of these materials may limit their biodistribution
in vivo (18). Thus, in addition to nanoparticle carriers,
there is also merit in exploring the use of molecular scale
conjugates or complexes of oligonucleotides for delivery
purposes. One approach has been to chemically conjugate
oligonucleotides with various peptide ligands, including
so-called ‘cell-penetrating peptides’ (CPPs). A number of
CPPs have been described; they are most commonly
polycationic sequences that seem to have the ability to
penetrate from the outside of the cell to the cytosol, and in
doing so to assist in delivery of linked ‘cargo’ molecules,
including peptides and proteins (19,20). A considerable
eﬀort has gone into the preparation and evaluation of
conjugates of CPPs and oligonucleotides; however, on the
whole this has been only modestly successful (21,22).
While our laboratory has reported some biological eﬀects
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tides (23,24), and others have reported on CPP–siRNA
conjugates (25,26), the prevailing literature suggests that
CPPs are only able to eﬀectively deliver oligonucleotides
with uncharged backbones, such as peptide nucleic acids
and morpholino compounds (27–31). Further, the con-
centrations needed to elicit biological eﬀects were often in
the micromolar range, higher than is usually deemed
desirable for potential therapeutic agents.
A potentially more promising strategy is to deliver
antisense and siRNA oligonucleotides via receptor-
mediated endocytosis by linking the oligonucleotide to a
targeting moiety that binds with high aﬃnity to a cell
surface receptor capable of undergoing internalization.
For example, an aptamer–siRNA conjugate targeting
prostate-speciﬁc membrane antigen (PSMA) was able to
eﬀectively deliver the associated siRNA to prostate cells
(32), while a single-chain antibody-protamine chimera,
when complexed to siRNA, was able to deliver the siRNA
to cells that expressed the target antigen (33). In addition,
a peptide that binds the IGF1-receptor was able to deliver
a peptide nucleic acid antisense moiety to the cytoplasm of
cells expressing the receptor (34).
In this report, we describe the preparation and charac-
terization of conjugates between an anionic antisense
oligonucleotide and a bivalent RGD peptide that binds
with high aﬃnity to the avb3 integrin (35). Members of
the integrin family of cell surface receptors provide
structural linkages between the extracellular matrix and
the cytoskeleton, but are also importantly involved in the
control of signal transduction pathways (36). The avb3
integrin is of particular interest in cancer since it is highly
expressed both in angiogenic endothelial cells and certain
types of malignant cells (37). Thus, it may provide a
means to selectively target growth-regulatory oligonucleo-
tides to tumors or tumor vasculature. In the current study,
the bivalent peptide was coupled to a ‘splice-shifting
oligonucleotide’ (SSO) designed to correct splicing of an
aberrant intron inserted into the ﬁreﬂy luciferase reporter
gene (38). Thus, successful delivery of the SSO to the cell
nucleus would result in up-regulation of luciferase activ-
ity. Using this approach we show that the bivalent RGD
peptide can eﬀectively deliver the SSO to avb3-expressing
melanoma cells in culture via a receptor-mediated
endocytotic process.
MATERIALS AND METHODS
Synthesis andchemical characterization of
peptide-oligonucleotide conjugates
The 20-O-Me phosphorothioate sequence termed oligonu-
cleotide 623 (50-GTT ATT CTT TAG AAT GGT GC-30)
and its conjugates, as well as mismatched controls, were
prepared as described subsequently.
Phosphoramidites, controlled pore glass supports
and other reagents. 50-O-(4,40-Dimethoxytrityl)-N-phe-
noxyacetyl-20-O-methyl-adenosine-30-O-[(b-cyanoethyl)-
(N,N-diisopropyl)]-phosphoramidite (20-O-Me-Pac-A-CE
Phosphoramidite), 50-O-(4,40-dimethoxytrityl)-N2-isopro-
pylphenoxyacetyl-20-O-methyl-guanosine-30-O-[(b-cyano-
ethyl)-(N,N-diisopropyl)]-phosphoramidite (20-O-Me-iPr-
Pac-G-CE Phosphoramidite), 50-O-(4,40-dimethoxytrityl)-
N-acetyl-cytidine-20-O-methyl-30-O-[(b-cyanoethyl)-
(N,N-diisopropyl)]-phosphoramidite (20-OMe-Ac-C-CE
Phosphoramidite), 1-O-(4,40-dimethoxytrityl)-hexyl-disul-
ﬁde-10-[(b-cyanoethyl)-(N,N-diisopropyl)]-phosphorami-
dite (Thiol-Modiﬁer C6 S-S), 1-O-(4,40-dimethoxytrityl)-
3-{O-[N-carboxy-(tetramethyl-rhodamine)-3-aminopro-
pyl]}-propyl-2-O-succinoyl-long chain alkylamino-
controlled pore glass (CPG) (30-Tamra CPG), 3H-1,2-
benzodithiole-3-one-1,1-dioxide (Beaucage Reagent) and
other reagents for DNA synthesis were purchased from
Glen Research (Sterling, VA, USA). 50-O-(4,40-dimethox-
ytrityl)-5-methyluridine-20-O-methyl-30-O-[(b-cyanoethyl)-
(N,N-diisopropyl)]-phosphoramidite (20-O-Me-T-CE
Phosphoramidite) was purchased from Chemgenes
(Ashland, MA, USA).
Synthesis, cleavage and de-protection of
oligonucleotides. Oligonucleotides were synthesized
using phosphoramidites of the ultraMILD-protected
bases indicated above on a 1mmol scale on 30-Tamra
CPG supports (500 ˚ A) using a AB 3400 DNA synthesizer
(Applied Biosystems, Foster City, CA, USA). The
coupling times for the phosphoramidites of ultraMILD-
protecting bases and 50-thiol linker were 360 and 600s,
respectively. 5-Ethylthio-1H-tetrazole was used as an
activator (0.25M solution in acetonitrile), 5% phenox-
yacetic anhydride in tetrahydrofuran/pyridine as a CAP
mix A, and Beaucage reagent was used to introduce the
internucleotide phosphorothioate backbone during oligo-
nucleotide synthesis. A 50-thiol linker was introduced at
the 50-end of the oligonucleotide.
Oligonucleotides were simultaneously cleaved from the
CPG support and deprotected using a mixture of tert-
butylamine:methanol:water(1:1:2)at558Cfor8h.Prior
todeprotection,theCPGsupportsweretreatedwitha10%
solution of diethylamine in acetonitrile. This removes
cyanoethyl protection and prevents elimination of the
30-Tamra linker from the oligonucleotide. This was done
with disposable syringes using 2 1ml solution for 5min
each followed by washing with acetonitrile and drying the
support with a stream of argon gas. The CPG support was
then transferred to a vial and 2ml deprotection solution
was added and heated for 8h at 558C. The oligonucleotide
solution was immediately evaporated to dryness, and
resuspended in 0.1M TEAA buﬀer for puriﬁcation.
Purification and structure determination. Puriﬁcation of
the oligonucleotides was carried out by reverse-phase
HPLC using a ZORBAX 300 SB-C18 column
(9.4mm 25cm) on a Varian HPLC system (ProStar/
Dynamax, Walnut Creek, CA) with a dual wavelength UV
detector. HPLC conditions were as follows: linear
gradient, % buﬀer B=10–30%/20min,  100%/30min,
4ml/min; buﬀer A contained 0.1M TEAA, pH 7.0 and
buﬀer B: acetonitrile; UV monitor: 254 and 550nm ( max
for Tamra). The oligos were collected and lyophilized.
Structures of the oligonucleotides were determined using
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time-of-ﬂight) mass spectroscopy in a positive ion mode on
a Voyager Applied Biosystem instrument (Foster City,
CA). The matrix used for preparing the oligonucleotide
samples was a mixture of 3-hydroxypicolinic acid
(50mgml
 1 in 50% aqueous acetonitrile) and diammo-
nium hydrogen citrate (50mgml
 1 in HPLC grade water).
The accuracy of the mass measurement was  0.02%.
Preparation of 50-thiol oligonucleotides. The 50-thiol func-
tionality was generated by treating the disulphide bond of
the oligonucleotide with 100mM of aqueous DTT in
0.1M TEAA buﬀer containing 1% triethylamine. After
overnight incubation, the reaction mixture was desalted
through a Sep-PAK C18 cartridge, and any residual
amount of DTT was removed by washing with 5%
acetonitrile in a 0.1M TEAA buﬀer. Finally, the Tamra-
623-SH oligonucleotide was eluted with 50% aqueous
acetonitrile and directly used for the conjugation reaction.
The structure of the thiol-containing oligonucleotide was
conﬁrmed by MALDI-TOF as described above.
Synthesis of bivalent RGD peptide–oligonucleotide
conjugates. The synthesis and characterization of similar
bivalent RGD peptides has been described elsewhere (35);
however, in the present case, a maleimide linker was
incorporated so as to allow conjugation with the oligonu-
cleotide. The cyclic RGD dimer (10mmol) was reacted with
maleimide NHS ester (15mmol) in borate buﬀer (0.05N,
pH 8.5) at room temperature. After 2h, RGD–maleimide
was isolated by semi-preparative HPLC with a 70% yield.
Mass spectrometry analysis [MALDI-TOF-MS: 1515.72
for [MH]
+ (C67H95N20O21, calcd [MW] 1515.69)] con-
ﬁrmed the product identiﬁcation. Thiol oligonucleotides
(316nmol in 50% aqueous CH3CN) were reacted with the
maleimide-containing bivalent RGD peptide (475nmol in
water) in a reaction buﬀer (ﬁnal salt concentration
adjusted to 400mM KCl, 40% aqueous CH3CN). The
reaction mixture was vortexed and allowed to stand for 3h,
and puriﬁed by HPLC using a 1ml Resource Q column
(GE Healthcare, Uppsala, Sweden) following a published
method (39). Buﬀers were as follows: buﬀer A, 20mM
Tris–HCl (pH 6.8), 50% formamide; buﬀer B, 20mM
Tris–HCl (pH 6.8), 400mM NaClO4, 50% formamide;
linear gradient, % buﬀer B=0–100%/20min, 3mlmin
 1;
UV monitor, 254 and 550nm. The puriﬁed conjugates were
dialyzed versus milli-Q water, and analyzed by MALDI-
TOF using a matrix that was a mixture of 2,6-dihydrox-
yacetophenon (20mgml
 1) and diammonium hydrogen
citrate (40mgml
 1) in 50% aqueous methanol. It should
be noted that various versions of the bivalent RGD
peptide–623 conjugate were made including with or
without the Tamra ﬂuorophore, as well as control
conjugates having an oligonucleotide with multiple mis-
matches in the 623 sequence (Table 1).
Celllines and plasmids
A375SM melanoma cells were obtained from Dr J. Bear
(University of North Carolina), and were cultured
in Dulbecco’s minimum essential medium (DMEM)
(Gibco/Invitrogen, Carlsbad, CA, USA) supplemented
with L-glutamine and 10% fetal bovine serum (FBS).
M21+ and M21  melanoma cell lines, having or lacking
avb3 integrin expression (40) were obtained from Dr
D. Cheresh (University of California, San Diego) and were
similarly maintained. Plasmid pLuc/705, containing an
aberrant intron inserted into the ﬁreﬂy luciferase coding
sequence, was a kind gift from Dr R. Kole, (University
of North Carolina) (38). Stable transfectants were
obtained by co-transfecting A375SM cells with one part
of hygromycin-resistant plasmid pcDNA3.1(+)/hygro
(Invitrogen) and 10 parts of pLuc/705 using Lipofectamine
2000 as per manufacturer’s instructions. Selection was
carried out in DMEM containing 200mg/ml hygromycin
and 10% FBS. The resulting pool of hygromycin-resistant
cells was referred to as A375SM-Luc705-B.
Oligonucleotide treatment and luciferase assay
A375SM-Luc705-B cells were plated on 12-well plates (at
1.0 or 1.5 10
5 cells per well in various experiments) in
DMEM supplemented with 10% FBS. The following day,
medium was changed to reduced serum OPTI-MEM I
(Gibco, Carlsbad, CA, USA). Cells were treated with
either free 623 oligonucleotide, 623 complexed with
Lipofectamine 2000 as per manufacturer’s instruction,
or RGD–623 conjugate or with mismatched control
oligonucleotides. Four hours after treatment, 1% FBS
was added to each well. Twenty-four hours after
oligonucleotide treatment, medium was replaced with
DMEM containing 1% FBS, and at various times
thereafter cell lysates were collected for luciferase assay.
Cells were usually harvested 48h after oligonucleotide
treatment, or at times indicated in the ﬁgures, and activity
determined using a Luciferase assay kit (Promega,
Madison, WI, USA). Measurements were performed on
a Monolight 2010 instrument (Analytical Luminescence
Laboratory, San Diego, CA, USA). In some cases, the
eﬀects of the RGD–623 conjugate were evaluated in the
presence of free monovalent cyclic RGDfV peptide
(Anaspec, San Jose, CA, USA).
Cell uptake,confocal fluorescence microscopy and
flow cytometry
Total cellular uptake of Tamra-labeled oligonucleotides
was monitored using a Nanodrop microﬂuorimeter
(Nanodrop Technologies, Wilmington, DE, USA).
After treatment with oligonucleotides the cells were
lysed in a mild non-ionic detergent buﬀer and the Tamra
Table 1. MALDI-TOF mass of oligonucleotides and their RGD
conjugates
Oligo/Conjugate MWCalcd MWFound
623-Tamra 7691.97 7691.80
HS-(CH2)6–623-Tamra 7910.74 7912.01
Bivalent-RGD-Mal-S-(CH2)6–623-Tamra 9427.32 9427.43
5MM623-Tamra 7620.00 7620.20
HS-(CH2)6–5MM623-Tamra 7833.26 7833.50
Bivalent-RGD-Mal-S-(CH2)6–5MM623-Tamra 9347.95 9345.50
623 sequence: 50-GTT ATT CTT TAG AAT GGT GC; 5MM623
sequence: 50-GTA ATT ATT TAT AAT CGT CC.
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linear standard curve of unconjugated Tamra in buﬀer.
Intracellular distribution of Tamra-labeled oligonucleo-
tides in living cells was examined using an Olympus
Confocal FV300 ﬂuorescent microscope with 60X-oil
immersion objective, as previously described (41).
Co-localization of Tamra-labeled oligonucleotides with
Alexa-488 labeled transferrin or 10000MW dextran
(Molecular Probes, Beaverton, OR, USA), as markers
for clathrin-coated vesicles or smooth vesicles, respectively
(42), was also done by confocal microscopy. Sub-cellular
localization of Tamra-labeled oligonucleotides in speciﬁc
endomembrane compartments was monitored by ﬁxing
cells with 4% paraformaldehyde followed by permeabili-
zation with methanol for 30s (43) and treatment with
primary antibody followed by Alexa488-labeled secondary
antibody. Antibodies to the following endomembrane
markers (40,44,45) were obtained from BD Biosciences
(San Jose, CA): caveolin-1 (caveolae), EAA1 (early
endosomes), p230TG (trans-Golgi), LAMP1 (lysosomes),
clathrin (coated vesicles). Primary and secondary anti-
bodies were used at a 1:1000 dilution. Visualization of
markers by confocal ﬂuorescence microscopy followed
previously described approaches (46,47). Expression levels
of avb3 were monitored by immunostaining with an anti-
human-avb3 monoclonal (Chemicon, Temecula, CA,
USA) followed by an Alexa 488 rabbit anti-mouse
secondary antibody, with analysis by ﬂow cytometry
using a DakoCytomation (Glostrop, Denmark) machine.
Cytochalasin D and b-cyclodextrin were purchased from
Sigma Chemical Co.
Toxicity studies
For short-term studies, cells were treated with various
concentrations of oligonucleotides or conjugates under the
same conditions as used for the luciferase-induction
experiments. After 48h in medium plus 1% FBS, cells
were trypsinized and viable cells were counted in a
Cellzone electronic particle counter (Elmhurst, IL).
Long-term toxicity was assessed using a colony-formation
assay. Thus, cells were treated with various concentrations
of oligonucleotides or conjugates under the same condi-
tions as used for the luciferase induction experiments.
Thereafter, cells from each treatment group were replated
in 6-well plates containing a mixture 1% low gelling
temperature agarose (SeaKem, Rockland, ME, USA) and
complete DMEM-H medium with 10% FBS. After 14
days, surviving colonies larger than 25 cells were counted.
Survival was expressed as colonies per 100 cells plated.
RESULTS
Oligonucleotide 623 is a 20-O-Me phosphorothioate
sequence that is designed to correct splicing of an aberrant
intron from thalassemic hemoglobin; this intron can be
inserted into various reporter genes, such as luciferase,
and correction of the splicing defect results in
up-regulation of gene expression (48,49). This provides a
sensitive and convenient positive readout for monitoring
delivery of splice switching oligonucleotides (SSOs) to the
cell nucleus, the compartment where splicing takes place.
It also avoids the typical pitfalls of many assays of
antisense or siRNA eﬀects that rely on inhibition of gene
expression and can thus be confounded by non-speciﬁc
toxicities. In the current report, we have linked the 623
SSO to a peptide that contains two modules of a cyclic
RGD sequence. This allows the bivalent peptide to bind
with high aﬃnity to the avb3 integrin (35), a cell surface
receptor that is highly expressed in angiogenic endothelial
cells and certain types of tumor cells, including the A375
melanoma cells used here.
Synthesis and characterization
The chemical structure of the bicyclic RGD peptide is
shown in Figure 1A. This peptide contains a maleimide
functionality that can be coupled with 50-thiol oligonu-
cleotide 623 via the Michael addition reaction as shown
in Figure 1B. We introduced a Tamra ﬂuorophore at the
30-end of the oligonucleotide and a thiol C-6S-S linker at
the 50-end. The DMTr-(CH2)6-S-S-(CH2)6-[623]-Tamra
oligonucleotide (1) was puriﬁed by RP-HPLC, and its
disulﬁde bridges were reduced with DTT solution to
generate highly reactive 50-HS-(CH2)6-[623]-Tamra oligo-
nucleotide (2).
The peptide conjugation reaction occurred between
the maleimide of the bicyclic RGD peptide and the 50 thiol
(-SH) of the oligonucleotide (2). The reaction proceeded
eﬃciently and >95% of the starting oligonucleotide (2)
was converted into conjugates with bicyclic RGD. The
conjugates were puriﬁed by ion-exchange chromatography
(Resource Q column) under highly denaturing conditions
(39) to avoid any sort of precipitation, although this was
not expected to be a problem for this type of peptide.
HPLC proﬁles for the puriﬁed bicyclic RGD–623 con-
jugate and for the thiol oligonucleotide (2) are given in
Figure 1C, which shows that the conjugate peak is clearly
resolved from the starting thiol oligonucleotide. After
dialysis and lyophilization, the conjugate re-dissolved in
sterile water without any diﬃculty. Similar approaches
were used for the preparation of other oligonucleotides
and conjugates. In each case, the structure of the ﬁnal
product was conﬁrmed by MALDI-TOF mass spectros-
copy. The characteristics of the various oligonucleotides
and conjugates synthesized are given in Table 1.
Dose–response studies
The RGD–623 conjugate, as well as ‘free’ 623, or 623
complexed with Lipofectamine 2000 were incubated with
A375SM-Luc705-B cells as described in Materials and
methods section and the cells were tested for luciferase
expression. As seen in Figure 2A, the RGD–623 conjugate
produced a signiﬁcant increase in luciferase expression
while the free 623 did not. The eﬀect of higher concentra-
tions of RGD–623 was  50% of that produced by the
623/cationic lipid complex. It should be noted that we
were not able to use >100nM oligonucleotide with the
Lipofectamine 2000 complexes because this material
became quite toxic at higher concentrations of oligonu-
cleotide. Although we have not performed a highly
detailed dose–response study, our current data suggests
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between 0 and 100nM and then begins to plateau. This
behavior is consistent with the known aﬃnities of the
bivalent RGD peptide and its conjugates for the avb3
integrin, these being approximately in the 15–30nM range
(35). Use of a control oligonucleotide or a control
RGD-conjugate, each having ﬁve mismatches in the 623
sequence, failed to produce an increase in luciferase
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Figure 1. (A) Chemical structure of the maleimide-bicyclic RGD peptide.
The maleimide reactive group is positioned mid-way along a linker that
joins the two cyclic RGD moieties. (B) Synthetic scheme for the
conjugation of oligonucleotide 623 to the bivalent RGD peptide. The
intermediates (1, 2) were puriﬁed after each step in the synthesis.
(I) 100mM DTT, 0.1M TEAA buﬀer, 1% triethylamine;
(II) maleimide-bicyclic-RGD peptide in H2O (1.5 equivalent), 400mM
KCl, 40% CH3CN, 3h, RT. (C) HPLC analysis of the RGD peptide–
oligonucleotide conjugate. HPLC analysis was performed as described
in Materials and methods section. The elution proﬁles of the 50-SH-30-
Tamra 623 oligonucleotide and its bivalent RGD conjugate are shown.
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Figure 2. Dose–response and speciﬁcity studies. (A) Cells were treated
with either 623-Tamra, RGD–623-Tamra conjugate or 623-Tamra
complexed with Lipofectamine 2000, as described in Materials and
methods section, and luciferase activity was determined after 48h and
expressed as relative luminescence units (RLUs) per 1.5 10
5 cells.
Black bars represent luciferase activity of 623-Tamra, patterned/striped
bars represent the RGD–623-Tamra conjugate and the gray bar
represents the activity of 100nM 623-Tamra transfected using
Lipofectamine 2000. (B) The eﬀect of 623-Tamra or RGD–623-
Tamra was compared to controls having ﬁve mismatched bases
(indicated as 5MM623). The conjugates or free oligonucleotide were
used at 200nM while the Lipofectamine 2000 complexes were used at
100nM oligonucleotide. Results (A and B) are the means and standard
errors of three determinations.
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response observed depends on speciﬁc base-pairing. We
also examined whether the presence of the Tamra
ﬂuorophore aﬀected the action of the 623 oligonucleotide
on luciferase expression. We found that neither the eﬀects
of RGD–623 nor of ‘free’ 623 delivered via lipofection
were altered by the inclusion of Tamra at the 30 position,
at concentrations up to 75nM; at concentrations
>100nM there was a slight augmentation of eﬀect by
Tamra presumably due to some hydrophobic binding of
the conjugate to the cell membrane (Supplementary Data).
Time–response studies
We examined the kinetics and duration of action of the
RGD–623 conjugate by harvesting the cells at various
times after the period of exposure to the oligonucleotide.
As seen in Figure 3, there was a striking diﬀerence between
the kinetics of the RGD–623 conjugate and the cationic
lipid/623 complex. Thus, the eﬀect of the RGD–623
conjugate on luciferase expression rose gradually with
time and reached a maximum at 72h (48h after removal
of the oligonucleotide). In contrast, the eﬀect of the
cationic lipid/623 complex was greatest at very early time
points after exposure to the oligonucleotide and declined
steadily thereafter. This indicates that the two modes of
delivery operate by very diﬀerent mechanisms. The
oligonucleotide delivered via cationic lipids seems to
rapidly go to the nucleus, while that delivered via the
peptide-conjugate seems to traﬃc through other intracel-
lular compartments and only gradually reach the nucleus
where the eﬀect on splicing takes place.
Total cellular uptake
We evaluated total cellular uptake of 623-Tamra or its
RGD-conjugate by incubating cells with various concen-
trations of these molecules and then measuring total
cell-associated ﬂuorescence as described in Materials
and methods section. As seen in Figure 4A, there
was approximately 2-fold greater uptake of the
RGD-conjugate as compared to the unconjugated oligo-
nucleotide at each concentration tested. The increased
uptake could largely be blocked by co-incubation with
excess free cyclic RGD peptide suggesting the involvement
of the avb3 integrin (data not shown). As another means of
clearly implicating avb3 in cellular accumulation of the
conjugate, we measured uptake of 623-Tamra or RGD–
623-Tamra by M21+ and M21  melanoma cells that have
or lack expression of the avb3 integrin (Supplementary
Data). As indicated in Figure 4B, there was substantially
more ( 3 ) uptake of the RGD-conjugate by the M21+
cells as compared to the M21  cells. In the M21  cells,
there was slightly greater uptake of the RGD–623-Tamra
conjugate as compared to the 623-Tamra control.
However, this might be due to the presence of other
RGD-binding integrins such as a5b1o ravb1 that could
associate with the conjugate, albeit with lower aﬃnity.
To determine whether incubation with RGD–623-
Tamra ‘down-regulates’ expression of its integrin receptor,
we examined cell surface levels of avb3 before and after
24h exposure to the RGD conjugate. As seen in
Figure 4C, exposure of the cells to 200nM of RGD–
623-Tamra, or 623-Tamra, had no eﬀect on the level of
cell surface avb3 expression. Thus, the data of Figure 4
indicate that a signiﬁcant portion of the uptake of the
RGD–oligonucleotide conjugate occurs via the avb3
integrin, but that this does not result in substantial net
loss of avb3 from the cell surface, presumably due to
eﬃcient recycling of the receptor.
Inhibition of function withexcess RGD peptide
We further tested the hypothesis that the RGD–623
conjugates that are functional in aﬀecting luciferase
splicing enter the cell via receptor-mediated endocytosis
involving the avb3 integrin. If that were the case, then the
biological eﬀect of RGD–623 should be blocked by
co-incubation with excess amounts of a ligand that binds
to the same site on avb3. As a blocking agent we utilized a
cyclic RGD peptide (RGDfV) that is known to be a
selective inhibitor of avb3 (50,51). Co-incubation with
increasing concentrations of this peptide led to a progres-
sive inhibition of the eﬀect of RGD–623-Tamra on
luciferase expression (Figure 5). This observation supports
the concept that the eﬀect of RGD–623-Tamra on splicing
largely depends on its initial uptake via the avb3 receptor.
Subcellular distribution
We examined subcellular distribution of the Tamra-
labeled oligonucleotides in living cells by confocal
ﬂuorescence microscopy (Figure 6A). In the case of cells
treated with 623-Tamra complexed with Lipofectamine
2000, a substantial amount of cell uptake was seen; this
was primarily associated with cytoplasmic vesicles, while a
fraction of the cells clearly had ﬂuorescence within the cell
nucleus. With the RGD–623-Tamra conjugate substantial
cellular uptake was observed; this was primarily asso-
ciated with cytoplasmic vesicles and there was no readily
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Lipofectamine 2000, as described in Materials and methods section,
and luciferase activity was determined at the times indicated. Black bars
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represent 100nM 623-Tamra transfected using Lipofectamine 2000, all
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Nucleic Acids Research, 2008, Vol. 36, No. 8 2769observable nuclear ﬂuorescence. In the case of ‘free’ 623-
Tamra, less uptake was observed, consistent with the
ﬁndings in Figure 4A. Co-incubation of the RGD–623-
Tamra conjugate with free RGD peptide substantially
reduced total cell-associated ﬂuorescence in the confocal
images (data not shown).
We undertook a preliminary investigation of the
subcellular traﬃcking of the RGD-conjugate, keeping in
mind that endosomal traﬃcking processes are extremely
complex (42,52). Using live cells, we examined the
colocalization of the RGD–623-Tamra conjugate with
transferrin or dextran, well-known markers, respectively
for clathrin-coated vesicle or smooth vesicle endocytosis.
At early time points (2h) there was no co-localization of
the RGD-conjugate with transferrin but there was
extensive co-localization with dextran (Figure 6B). At
later times (24h) there was substantial co-localization of
the RGD-conjugate with either the transferrin or dextran
markers. These observations suggest the RGD–oligonu-
cleotide conjugate initially enters cells via a non-clathrin-
mediated endocytic process, but eventually traﬃcks
through various endomembrane compartments including
some that can also be accessed by transferrin.
To further pursue the subcellular fate of the RGD-
conjugate we examined its distribution as compared to
well-known markers for several endomembrane compart-
ments, using immuno-localization in ﬁxed and permeabil-
ized cells. It should be noted that we carefully examined
the ﬂuorescence patterns of the RGD–623-Tamra con-
jugate in live and ﬁxed/permeabilized cells and did not
observe any signiﬁcant diﬀerences, thus indicating that the
conjugate does not re-localize upon ﬁxation and perme-
abilization. As shown in Figure 7A, at early times (2–6h)
there was signiﬁcant co-localization of RGD–623-Tamra
with caveolin-1. Long ‘strands’ of caveolin-1-positive
endosomes were observed near cell edges, as is sometimes
seen for this marker, and some of these apparently
contained RGD–623-Tamra. We also noted early (2–6h)
co-localization of RGD–623-Tamra with avb3, as one
might expect (Figure 7B). Finally, at late (24h) but not
early (6h or less) times, we observed some co-localization
of RGD–623-Tamra with TG230, a marker for the trans-
Golgi compartment (Figure 7C). We did not observe
signiﬁcant co-localization of RGD–623-Tamra with other
markers tested including EAA1, LAMP1 and clathrin; the
last being consistent with our live cell observations
(Figure 6B) that the conjugates do not use a clathrin-
coated vesicle pathway. While there are always concerns
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Figure 4. (A) Total cell uptake. Cells in 12-well plates were treated with
various concentrations of free 623-Tamra, or RGD–623-Tamra, for 4h in
OptiMEM at 378C, then 1% FBS was added to each well. After 24h of
further treatment, the cells were rinsed three times in buﬀered saline
solution and then lysed. Total cell-associated Tamra was measured using
a Nanodrop ﬂuorimeter as described in Materials and methods section.
Results represent means and standard errors of triplicate determinations
and are expressed as relative ﬂuorescence units (RFUs) per microgram
cell protein. (B) Uptake of RGD–623-Tamra depends on avb3.
Both avb3-positive M21+ and avb3-negative M21  human melanoma
cells were exposed to several concentrations of RGD–623-Tamra
or 623-Tamra. Total cell-associated Tamra was measured using a
Nanodrop ﬂuorimeter as described in Materials and methods section.
Results represent means and standard errors of triplicate determinations
and are expressed as RFUs per microgram cell protein. (C) Lack of down-
regulation of avb3 by RGD–623. A375SM-Luc705-B cells were main-
tained as controls or were treated with 200nM RGD–623-Tamra or
623-Tamra for 24h; thereafter, avb3 levels were determined by immuno-
staining with anti- avb3 and ﬂow cytometry as described in Materials and
methods section. (1) Cells not stained with primary anti- avb3; (2) control
cells stained with anti- avb3, (3) cells treated with 200nM RGD–623-
Tamra and stained with anti- avb3, (4) cells treated with 200nM 623-
Tamra and stained with anti- avb3. Ordinate, number of cells; abcissa, log
ﬂuorescence intensity.
2770 Nucleic Acids Research, 2008, Vol. 36, No. 8about relying on ﬂuorophore labels, the fact that we are
using rather stable 20-O-Me phosphorothiate compounds
makes it likely that the 30-Tamra label provides a
reasonably good initial indication of the subcellular
distribution of the oligonucleotide. Similar ﬂuorophore-
labeled antisense or siRNA oligonucleotides have been
widely used to trace subcellular distributions for periods
up to 24h (39,53).
We also examined the eﬀects of some known inhibitors
of endocytosis on the ability of cells to accumulate RGD–
623-Tamra. As seen in Figure 7D, both b-cyclodextrin and
cytochalasin D blocked the uptake of the conjugate. At
the non-cytotoxic concentrations used here, b-cyclodex-
trin is thought to interfere with endocytosis mediated by
lipid raft-rich structures, including caveolae, via depletion
of cholesterol (54), while cytochalasin D blocks actin
ﬁlament function (55), which is necessary for virtually all
forms of endocytosis (52). While use of pharmacological
inhibitors needs to be interpreted cautiously because of
possible side-eﬀects, these results do support the ﬂuores-
cence microscopy observations and suggest that the
RGD–oligonucleotide conjugate enters cells via caveolae
and possibly other lipid raft-rich smooth endocytotic
vesicles.
Toxicity
We have evaluated the short-term toxicity of the
oligonucleotides and conjugates used in these studies.
As seen in Figure 8, there was little eﬀect of either the
623-Tamra oligonucleotide or its RGD-conjugate at
concentrations up to 1000nM. Some cell rounding was
observed at the higher concentrations of RGD–oligonu-
cleotide conjugate, but this did not result in signiﬁcant cell
loss. Although high concentrations of the RGD-conjugate
might be expected to perturb adhesion mediated by
RGD-binding integrins, in the experimental setting the
cells have the opportunity to lay down extracellular matrix
and may be anchored to that matrix by both RGD-
binding and non-RGD-binding integrins, for example,
those involved in binding to collagen or laminin (36).
Some toxicity was observed for the Lipofectamine 2000/
623-Tamra complex at 100nM oligonucleotide, while use
of 200nM was very toxic (data not shown). The increased
toxicity of the cationic lipid complexes may be due in part
to the fact that they are very eﬀective in delivering
oligonucleotides to the cell. We also evaluated long-term
toxicity using a colony-formation assay. As seen in
Table 2 there was little eﬀect of RGD–623-Tamra on the
long-term growth abilities of the cells when treated with
doses up to 1000nM. Thus the RGD–oligonucleotide
conjugates seem to be well-tolerated by cells over and
above the concentration range needed to obtain signiﬁcant
eﬀects in terms of splice correction of the luciferase
reporter gene.
DISCUSSION
In this report, we have examined the ability of a bivalent
RGD peptide to deliver an antisense oligonucleotide to
cells via targeting a speciﬁc cell surface receptor, the avb3
integrin. The 20-O-Me phosphorothioate oligonucleotide
used here (oligonucleotide 623) was designed to correct
the splicing of an aberrant intron inserted into the
luciferase reporter gene. Thus successful delivery of the
623 oligonucleotide to the nucleus is reﬂected by an
up-regulation of luciferase expression. Dose–response
studies monitoring luciferase induction indicated that the
RGD–623 conjugate displayed progressively increasing
activity in the 5–100nM range but that activity plateaued
at higher concentrations; this may be due to saturation of
the avb3 receptor by the conjugate. The fact that
biological eﬀects are attained in the nanomolar range
diﬀerentiates the RGD–623 conjugate from other peptide–
oligonucleotide conjugates employing various cell-
penetrating peptides, since in those cases micromolar
concentrations were usually required (21,22). The max-
imum eﬀects produced by the RGD–623 conjugates
ranged from 30% to 60% of that produced by delivering
the 623 sequence with Lipofectamine 2000. However, the
toxicities associated with cationic lipids make them
questionable candidates for in vivo delivery (56), while
RGD peptide-conjugates are relatively non-toxic even at
concentrations well above those needed to elicit a
pharmacological eﬀect, and may thus have some potential
for in vivo applications. The kinetics of the luciferase
expression produced by the RGD–623 conjugate entailed
a gradual rise and subsequent decline; this would be
consistent with initial entry into an endosomal compart-
ment followed by gradual release. In contrast, delivery
mediated by cationic lipids results in an initial burst of
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Figure 5. Inhibition of eﬀect with excess RGD peptide. Free RGDfV
peptide at the indicated concentrations was added to the cells 30min
prior to treatment with either 623-Tamra or RGD-623-Tamra
conjugate, as described in Materials and methods section. Luciferase
activity was determined after 48h. The dotted line represents luciferase
activity of 200nM 623-Tamra, and the solid line represents 200nM
RGD–623-Tamra conjugate. Results are the means and standard errors
of triplicate determinations.
Nucleic Acids Research, 2008, Vol. 36, No. 8 2771luciferase activity followed by a steady decline. Thus the
traﬃcking and delivery mechanisms involved in the two
situations are quite distinct. Both cell uptake and
biological eﬀects of the RGD–623 conjugate were blocked
by co-incubation with excess of a monovalent cyclic RGD
peptide that is a speciﬁc ligand for the avb3 integrin.
Additionally, cell uptake of the conjugate was higher in an
avb3-positive melanoma sub-line than in its avb3-negative
version. These results strongly suggest that the uptake and
delivery process involves receptor-mediated endocytosis of
the peptide conjugate.
Using conventional confocal ﬂuorescence microscopy
we have observed that the RGD–623-Tamra conjugate is
taken up to a greater degree than the unconjugated ‘free’
623 oligonucleotide, and that ﬂuorophore-labeled RGD-
conjugates accumulate primarily in cytoplasmic vesicles,
with little evidence of nuclear accumulation. However, a
small but functionally signiﬁcant fraction of the conjugate
must reach the nucleus, since substantial up-regulation
of luciferase activity is observed, and RNA splicing
only takes place within the nuclear compartment (57).
Recent studies of conjugates between CPPs and PNA
oligonucleotides have also found that eﬀects on splicing
can be attained under circumstances where little or
no nuclear localization is observable by ﬂuorescence
microscopy (28).
In these studies, we have made use of a relatively stable
maleimide coupling to join the RGD-peptide and the
oligonucleotide, and have not explored the impact of
linker stability on biological outcomes. In previous
studies, both bioreversible S–S linkages and more stable
linkages have been used successfully with peptide–
oligonucleotide conjugates (21,22).
There have been previous reports of RGD-conjugated
oligonucleotides (58) as well as reports of a variety
of strategies for peptide–oligonucleotide conjugation
(59–61). However, the present report diﬀers from earlier
studies in two ways. First, we are making use of a dimeric
RGD moiety that has a substantially higher aﬃnity than
previous RGD ligands. Second, we have undertaken
more extensive biological characterization of the RGD–
oligonucleotide conjugates than was the case in previous
studies. In other contexts, RGD ligands have been widely
used to target a variety of drugs, imaging agents,
macromolecules and nanocarriers. Thus, there is an
extensive literature on the use of mono- and multi-valent
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Figure 6. (A) Subcellular distribution of the conjugate. A375SM-Luc705-B cells were treated with either 623-Tamra, RGD–623-Tamra conjugate
(both 200nM) or with 623-Tamra complexed with Lipofectamine 2000 (100nM), as described in Materials and methods section. Cells were observed
using confocal ﬂuorescence microscopy. Care was taken to make sure images were acquired from optical sections within the cell. Panel (1) RGD–623-
Tamra conjugate, Panel (2) 623-Tamra, Panel (3) 623-Tamra complexed with Lipofectamine 2000. Images shown are overlaps of the Tamra-
ﬂuorescence and phase contrast images and are typical of multiple observations. In (1) white arrows indicate the position of the nucleus, while in (3)
black arrows indicate nuclei that have accumulated Tamra-oligonucleotide. (B) Co-localization with endosomal pathway markers. RGD–623-Tamra
oligonucleotide conjugate (100nM) was co-incubated with: (1) Transferrin–Alexa 488 (200nM) for 2h: (2) Transferrin–Alexa 488 (200nM) for 24h;
(3) Dextran–Alexa 488 (2 mM) for 2h; (4) Dextran–Alexa 488 (2 mM) for 24h. Live cells were observed by diﬀerential interference contrast (DIC) and
confocal ﬂuorescence microscopy as described in Materials and methods section. Concentrations of Alexa 488 transferrin and dextran were chosen to
provide brightness similar to the Tamra conjugate. Panel (1) shows no overlap of RGD–623-Tamra (red) and Transferrin–Alexa 488 (green) at 2h.
Panel (3) shows substantial overlap (yellow-orange) of RGD–623-Tamra and Dextran–Alexa 488at 2h. Panels (2) and (4) show substantial overlap
of RGD–623-Tamra with both Alexa 488 markers (yellow-orange areas) after 24h.
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Figure 7. Co-localization with markers of endomembrane compartments and eﬀects of inhibitors. Cells were treated with 50 nM RGD–623-Tamra
for various periods and were then ﬁxed, permeabilized and stained with antibodies to markers of various sub-cellular compartments, followed by
Alexa 488 secondary antibody, as described in Materials and methods section. Fletches and boxes indicate areas of co-localization; boxed areas are
expanded at higher magniﬁcation. (A) Co-localization with caveolin-1at 6h. (B) Co-localization with avb3at 6h. Note that similar patterns were
observed during the period 2–6h. (C) Co-localization with a trans-Golgi marker (TGN 230) at 6 or 24h. (D) Cells were treated with cytochalasin D
or b-cyclodextrin at the indicated concentrations for 15min and then 100nM RGD–623-Tamra was added. Total cell uptake after 4h was measured
using a Nanodrop ﬂuorimeter as described in Materials and methods section. No loss of cell viability was detected at the concentrations used,
although the highest concentration of cytochalasin D caused some cell rounding. Results represent means and standard errors of triplicate
determinations and are normalized based on cells receiving no inhibitor as 100%.
Nucleic Acids Research, 2008, Vol. 36, No. 8 2773RGD peptides linked to PET, SPECT, MRI and
ﬂuorescence imaging agents for non-invasive visualization
of the distribution of avb3 integrin in tumors and in
angiogenic vasculature (62–64). RGD ligands have also
been linked directly to drugs (35) or, in polyvalent form,
to drug–albumin conjugates (65). Various nanocarriers
including polymers and Q-dots have also been targeted to
cells using RGD ligands (66). These multiple studies attest
to the value of high-aﬃnity RGD ligands as a means to
attain receptor-selective targeting. There has also been a
good deal of interest in use of other receptor-selective
ligands for targeted delivery of oligonucleotides, primarily
in the context of nanocarriers (67). For example,
transferrin has been used to promote selective uptake of
cationic nanocarrier–siRNA complexes by tumors (13),
while folate has been used to target polyethyleneimine–
siRNA (PEI–siRNA) complexes to cells overexpressing
the folate receptor (68).
The mechanism(s) by which receptor-mediated endocy-
tosis enhances the activity of anionic antisense and
siRNA oligonucleotides is unclear. Obviously one aspect
is the increased intracellular uptake of the ligand–
oligonucleotide conjugate compared to free oligonucleo-
tide. However, this cannot be the only factor involved,
since we and others have found that increased accumula-
tion of anionic oligonucleotides caused by conjugation or
complexation with polycationic peptides or polymers does
not necessarily result in biologically eﬀective delivery
(21,22,39,69). In the cases of cationic lipids, or polymers
with secondary amines such as PEI, their eﬃcacy as nucleic
acid carriers seems to be due to endosome-disrupting
eﬀects, thus allowing release of the active material into the
cytosol (70); however, such endosome-damaging eﬀects are
unlikely when using RGD peptides as carriers.
An alternative mechanism may involve the partic-
ular intracellular traﬃcking pathway of the RGD–
oligonucleotide conjugates as they are initially trans-
ported by integrins. There are several distinct mechanisms
of endocytosis, each leading to endosomal traﬃcking
patterns that have unique as well as overlapping features
(42). Integrins are known to recycle via internalization into
endosomal compartments (71), but the exact pathways and
mechanisms involved are not fully resolved. Some studies
indicate that the avb3 integrin is normally internalized via
caveolae and then takes the so-called ‘long loop’ Rab
11-dependent recycling pathway back to the plasma
membrane through the perinuclear recycling compartment
(71,72). Our studies of the traﬃcking of the RGD-
conjugate suggest that initial uptake involves caveolae
and possibly other smooth, non-clathrin-coated vesicles
andthatsomeoftheconjugateiseventuallydeliveredtothe
trans-Golgi. Thus, the initial phase of uptake seems
consistent with the path described for the avb3 integrin,
but later phases seem distinct. This is not surprising since
ligands and their receptors often diverge during intracel-
lular traﬃcking. In an interesting parallel, recent studies
have suggested that traﬃcking through the Golgi is also a
productive route for functional delivery of siRNA (53,73).
We have noticed that conjugation of the RGD moiety
results in only a 2- to 3-fold increase in cell uptake versus
the unconjugated 623 oligonucleotide, but a several-fold
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Figure 8. Short-term toxicity of 623–RGD conjugates. Cells were
treated with either 623-Tamra, 623-Tamra complexed with
Lipofectamine 2000 or RGD–623-Tamra conjugate, as described in
Materials and methods section, and viable cell numbers were
determined after 48h by using a particle counter. Gray bars represent
cell numbers of various controls i.e. cells treated with Lipofectamine
2000 (Lipo), and 623-Tamra complexed with Lipofectamine 2000. Black
bars represent cell numbers for 623-Tamra, and patterned/striped bars
represent RGD–623-Tamra conjugate, all at the indicated concentra-
tions. Results are means and standard errors of three determinations.
Table 2. Lack of long-term toxicity of RGD–oligonucleotide conjugates
Material tested in soft
agar assay
Lipofectamine
2000 Control
Lipofectamine+
100nM 623 Tamra
50nM
623-Tamra
500nM
623-Tamra
50nM
RGD–623-Tamra
250nM
RGD–623-Tamra
1000nM
RGD–623-Tamra
Colonies formed/100
cells plated
13.3 3.0 13.8 2.0 14.8 3.0 13.0 2.5 15.3 2.5 13.7 1.2 14.0 2.0
A373SM-Luc 705B melanoma cells were treated with the indicated materials under the same conditions as those used for the luciferase induction
assays. Thereafter, cells were harvested, diluted and suspended in soft agar in 6-well plates with complete growth medium. Plates were incubated for
14 days and colonies >25 cells were counted. Results are shown as colonies per 100 cells plated and are the means and SDs of at least 6 wells per
treatment. Note: colony formation by untreated melanoma cells was not diﬀerent from that of the Lipofectamine 2000 control.
2774 Nucleic Acids Research, 2008, Vol. 36, No. 8increase in biological eﬀect. This hints that the initial
uptake pathway may aﬀect the ultimate delivery event;
however, for the present this remains an untested hypoth-
esis. Conﬁrmation will require a much more detailed
analysis of the subcellular traﬃcking pattern of this and
other conjugates in relation to their biological eﬀects.
In any case, the apparent eﬀectiveness of the RGD–
oligonucleotide conjugates in attaining splice correction
suggests that their mechanism of action will warrant
further investigation both in cell culture and in the in vivo
context.
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